Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Nov;64(Suppl 4):iv29–iv30. doi: 10.1136/ard.2005.042390

Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor α

K Winthrop
PMCID: PMC1766906  PMID: 16239382

Full Text

The Full Text of this article is available as a PDF (42.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend S. M., Breedveld F. C., van Dissel J. T. TNF-alpha blockade and tuberculosis: better look before you leap. Neth J Med. 2003 Apr;61(4):111–119. [PubMed] [Google Scholar]
  2. Ellerin Todd, Rubin Robert H., Weinblatt Michael E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003 Nov;48(11):3013–3022. doi: 10.1002/art.11301. [DOI] [PubMed] [Google Scholar]
  3. Gardam Michael A., Keystone Edward C., Menzies Richard, Manners Steven, Skamene Emil, Long Richard, Vinh Donald C. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003 Mar;3(3):148–155. doi: 10.1016/s1473-3099(03)00545-0. [DOI] [PubMed] [Google Scholar]
  4. Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–1104. doi: 10.1056/NEJMoa011110. [DOI] [PubMed] [Google Scholar]
  5. Mohan Aparna K., Coté Timothy R., Block Joel A., Manadan Augustine M., Siegel Jeffrey N., Braun M. Miles. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004 Jul 16;39(3):295–299. doi: 10.1086/421494. [DOI] [PubMed] [Google Scholar]
  6. Nolan C. M., Goldberg S. V., Buskin S. E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999 Mar 17;281(11):1014–1018. doi: 10.1001/jama.281.11.1014. [DOI] [PubMed] [Google Scholar]
  7. Pai Madhukar, Riley Lee W., Colford John M., Jr Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004 Dec;4(12):761–776. doi: 10.1016/S1473-3099(04)01206-X. [DOI] [PubMed] [Google Scholar]
  8. Singh N., Paterson D. L. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998 Nov;27(5):1266–1277. doi: 10.1086/514993. [DOI] [PubMed] [Google Scholar]
  9. Tufariello JoAnn M., Chan John, Flynn JoAnne L. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003 Sep;3(9):578–590. doi: 10.1016/s1473-3099(03)00741-2. [DOI] [PubMed] [Google Scholar]
  10. Wallis R. S., Broder M. S., Wong J. Y., Hanson M. E., Beenhouwer D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004 Apr 15;38(9):1261–1265. doi: 10.1086/383317. [DOI] [PubMed] [Google Scholar]
  11. Wallis Robert S., Kyambadde Peter, Johnson John L., Horter Libby, Kittle Rodney, Pohle Monika, Ducar Constance, Millard Monica, Mayanja-Kizza Harriet, Whalen Christopher. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004 Jan 23;18(2):257–264. doi: 10.1097/00002030-200401230-00015. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES